Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S418000, C548S469000, C548S484000, C548S486000, C548S487000
Reexamination Certificate
active
10506175
ABSTRACT:
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I
REFERENCES:
patent: 3558653 (1971-01-01), Coyne et al.
patent: 3705869 (1972-12-01), Benedetto et al.
patent: 4016173 (1977-04-01), Darmory et al.
patent: 4053483 (1977-10-01), Pujol et al.
patent: 4904575 (1990-02-01), Ono et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5914431 (1999-06-01), Fennhoff
patent: 5994544 (1999-11-01), Jones et al.
patent: 6008210 (1999-12-01), Weber
patent: 6017924 (2000-01-01), Edwards et al.
patent: 6093708 (2000-07-01), Weber
patent: 6121450 (2000-09-01), Jones et al.
patent: 6147066 (2000-11-01), Petit et al.
patent: 6166013 (2000-12-01), Coghlan et al.
patent: 6329416 (2001-12-01), Grubb et al.
patent: 1 420 310 (1976-01-01), None
patent: 757 530 (1980-08-01), None
patent: 755782 (1980-08-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO 00/06137 (2000-02-01), None
patent: WO 01/19770 (2001-03-01), None
patent: WO 01/52847 (2001-07-01), None
Petynin et al., Zhurnal Obshchei Khimii (1957), 27, 731-4.
Klumpp et al., J. Org. Chem., 1998, 63, 4481-4484.
Neel et al., Bio. & Med. Chem. Lett., 15, 2005, 2553-2557.
Neel, et al., Bioorganic & Medicinal Chemistry Letters, vol. 15, 2005, pp. 2553-2557.
Witkop, Bernhard, “Two-fold Wagner-Meerwein Rearrangements,” Journal of the American Chemical Society, vol. 73, pp. 5664-5669; XP002244339 (1951).
Klumpp, D, et al., “Preparation of 3,3-Diaryloxindoles by Superacid-induced condensation of Isatins and aromatics with a Combinatorial Approach,” Journal of Organic Chemistry, vol. 63, pp. 4481-4484; XP002244340 (1998).
Petyunin, P, et al., “N-Alkyl derivatives of 3,3-diaryloxindoles,” Zhurnal Obshchei Khimii, vol. 27, pp. 1554-1557; XP009012299 (1957).
Brown Matthew Lee
Grese Timothy Alan
Jadhav Prabhakar Kondaji
Lander Peter Ambrose
Neel David Andrew
Chung Susannah
Eli Lilly and Company
McKane Joseph K.
Wilson Alexander
LandOfFree
Dihydroindol-2-one derivatives as steroid hormone nuclear... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydroindol-2-one derivatives as steroid hormone nuclear..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroindol-2-one derivatives as steroid hormone nuclear... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794639